Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )

AIMS: In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic hypothesis. METHODS AND RESULTS: dal-GenE was a double-blind tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tardif, Jean Claude, Pfeffer, Marc A, Kouz, Simon, Koenig, Wolfgang, Maggioni, Aldo P, McMurray, John J V, Mooser, Vincent, Waters, David D, Grégoire, Jean C, L’Allier, Philippe L, Wouter Jukema, J, White, Harvey D., Heinonen, Therese, Black, Donald M, Laghrissi-Thode, Fouzia, Levesque, Sylvie, Guertin, Marie Claude, Dubé, Marie Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Fast track
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565632/
https://www.ncbi.nlm.nih.gov/pubmed/35856777
http://dx.doi.org/10.1093/eurheartj/ehac374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565632/
https://www.ncbi.nlm.nih.gov/pubmed/35856777
http://dx.doi.org/10.1093/eurheartj/ehac374

Ejemplares similares